In our cohort, activating JAK3 mutations were found in 11.5% of patients, reinforcing the importance of genomic screening to identify MF patients who may benefit from JAK inhibitors as a targeted, mechanism-based treatment strategy. The gene discussed is JAK3; the disease is mycosis fungoides.